Rina L. Welkie

Dear Editor, Despite recent advances in the treatment of systemic aggressive B-cell non-Hodgkin lymphomas (B-NHL), central nervous system (CNS) involvement remains a therapeutic challenge and is associated with dismal outcomes [1]. Chimeric antigen receptor (CAR) T-cell therapy achieves high overall response rates (ORR) in patients with CNS involvement, but responses are often short-lived (1-year progression-free survival (PFS) of 16–48%) [2,3,4,5].